Transplant Immunosuppression: Calcineurin Inhibitors, mTOR Inhibitors, and Antimetabolites

T-cell activation begins with antigen recognition through the T-cell receptor, which raises intracellular calcium and activates the calcium-calmodulin complex. This complex stimulates calcineurin, a serine-threonine phosphatase that dephosphorylates nuclear factor of activated T cells (NFAT), allowing it to translocate into the nucleus and drive transcription of interleukin-2 and other T-cell activation genes.

Cyclosporine binds cyclophilin, a cytoplasmic immunophilin, forming a cyclosporine-cyclophilin complex that inhibits calcineurin. Tacrolimus (also called FK-506) binds a different immunophilin, FK-binding protein 12 (FKBP-12), forming a tacrolimus-FKBP-12 complex that likewise inhibits calcineurin. Both complexes prevent NFAT dephosphorylation, blocking interleukin-2 transcription and halting T-cell activation and proliferation. Tacrolimus is approximately 100-fold more potent than cyclosporine on a weight basis and has largely replaced cyclosporine as the calcineurin inhibitor of choice in kidney, liver, heart, and lung transplantation.

Both calcineurin inhibitors have highly variable oral bioavailability — cyclosporine averages 20 to 50% depending on formulation, and tacrolimus averages 25% with a wide range. Both are extensively metabolized by cytochrome P450 3A4 (CYP3A4) and the related CYP3A5 isoform in the liver and intestinal wall, with P-glycoprotein serving as an important efflux transporter. CYP3A5 genetic polymorphisms are clinically relevant for tacrolimus: patients who express functional CYP3A5 (more common in patients of African ancestry) require substantially higher doses to reach target trough concentrations.

Both drugs distribute extensively into erythrocytes — tacrolimus approximately 75 to 80%, cyclosporine approximately 60% — so therapeutic drug monitoring samples must be collected in ethylenediaminetetraacetic acid-anticoagulated whole blood, not plasma. Trough concentrations drawn immediately before the morning dose (C0) are the standard monitoring parameter. For tacrolimus in kidney transplant, target troughs are typically 8 to 12 nanograms per milliliter in the early post-transplant period and 5 to 8 nanograms per milliliter during maintenance. Both drugs are eliminated primarily through biliary excretion; dose adjustment for renal impairment is not required on a pharmacokinetic basis, though both agents cause nephrotoxicity that limits their use as renal function declines.

Sirolimus and everolimus are macrolide compounds that, like tacrolimus, bind FKBP-12. However, the sirolimus-FKBP-12 complex does not inhibit calcineurin; instead it inhibits mammalian target of rapamycin complex 1 (mTORC1), a serine-threonine kinase that integrates nutrient, energy, and growth factor signals to regulate protein synthesis and cell cycle progression from G1 to S phase. In the context of T-cell immunosuppression, mammalian target of rapamycin inhibitors block the proliferative response to interleukin-2 downstream of calcineurin — which is why the combination of a calcineurin inhibitor (suppressing interleukin-2 production) with a mammalian target of rapamycin inhibitor (blocking the response to interleukin-2) produces synergistic immunosuppression and allows lower doses of each agent.

Both sirolimus and everolimus are metabolized by CYP3A4 and P-glycoprotein, creating drug interaction profiles identical to those of the calcineurin inhibitors. Sirolimus has a half-life of approximately 60 hours, allowing once-daily dosing; everolimus has a shorter half-life of approximately 28 to 30 hours and is dosed twice daily. Therapeutic drug monitoring is required for both. The principal toxicities unique to this class are pulmonary toxicity (sirolimus-induced pneumonitis occurs in 3 to 11% of patients and can range from asymptomatic infiltrates to organizing pneumonia requiring drug discontinuation) and impaired wound healing (mammalian target of rapamycin inhibitors inhibit fibroblast proliferation, increasing the risk of wound dehiscence, and are typically avoided in the first 4 to 12 weeks after transplant surgery). Hypertriglyceridemia is prominent, peripheral edema is common, and oral mucositis is a frequent complaint.

Azathioprine is a prodrug cleaved to 6-mercaptopurine, which is converted along competing metabolic pathways. The anabolic pathway via hypoxanthine-guanine phosphoribosyltransferase generates thioguanine nucleotides, the active immunosuppressive metabolites that incorporate into DNA and inhibit purine synthesis. The catabolic pathway via xanthine oxidase generates inactive thiouric acid. Thiopurine methyltransferase (TPMT) methylates 6-mercaptopurine to an inactive metabolite, shunting drug away from the active pathway.

The most dangerous drug interaction with azathioprine is coadministration with allopurinol or febuxostat, both xanthine oxidase inhibitors used for gout. Blocking xanthine oxidase causes four-fold accumulation of thioguanine nucleotides, producing severe, potentially fatal myelosuppression (pancytopenia). This combination is absolutely contraindicated unless the azathioprine dose is reduced by 67 to 75%, with weekly complete blood count monitoring.

TPMT activity is governed by common pharmacogenomic polymorphisms. Approximately 89 to 94% of individuals are homozygous for the high-activity wild-type allele and metabolize azathioprine normally. Approximately 6 to 11% are heterozygous carriers of a low-activity variant (TPMT*3A is most common in patients of European ancestry; TPMT*3C is more prevalent in patients of Asian and African ancestry) and require dose reduction of 30 to 50%. Approximately 0.3% are homozygous for low-activity alleles and develop profound myelotoxicity at standard doses. TPMT genotyping or phenotyping before initiating azathioprine is recommended. NUDT15 polymorphisms, more prevalent in patients of East Asian ancestry, also predict thiopurine myelotoxicity and should be tested in patients of relevant ancestry.

Mycophenolate mofetil is a prodrug hydrolyzed to mycophenolic acid (MPA), which inhibits inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo purine synthesis pathway. Lymphocytes are uniquely dependent on de novo purine synthesis and cannot effectively use the salvage pathway, making IMPDH inhibition selectively immunosuppressive for lymphocytes. Mycophenolic acid undergoes extensive enterohepatic recirculation, producing a secondary plasma peak at 6 to 12 hours after dosing.

Mycophenolate mofetil has largely replaced azathioprine in transplant protocols because of superior efficacy and a more favorable hematological safety profile. Its principal toxicities are gastrointestinal — nausea, vomiting, diarrhea, and abdominal cramping in 30 to 45% of patients — and dose-dependent. Gastrointestinal symptoms often improve with dose reduction or switching to enteric-coated mycophenolate sodium. Mycophenolate mofetil is a potent human teratogen, causing cleft palate, ear abnormalities, limb hypoplasia, and cardiac defects in up to 25% of exposed pregnancies. All women of childbearing potential must use reliable contraception during therapy. Azathioprine is the preferred antimetabolite when maintenance immunosuppression is required during pregnancy.